过氧化物酶体增殖物激活受体γ激动剂与肠纤维化的研究进展

摘要

肠纤维化是炎症性肠病的常见并发症之一,晚期表现为肠壁结构破坏及瘢痕收缩式肠腔狭窄,其形成机制尚不清楚.虽然目前临床用于治疗炎症性肠病的措施有一定缓解炎症的作用,但不能扭转肠纤维化的发展进程及其引起的肠道狭窄、肠梗阻等并发症.胞外基质在肠纤维化进程中扮演重要角色,其在肠壁的过度沉积促进纤维化发生.而过氧化物酶体增殖物激活受体γ( PPARγ)的活化或激动剂在器官纤维化的发生、发展过程中有调节作用,可减缓纤维化进程.目前,其已在肺纤维化、肝纤维化等纤维化疾病中表现出抗纤维化作用,未来PPARγ激动剂将成为肠纤维化疾病治疗的新靶点.%Intestinal fibrosis is one of common complications of inflammatory bowel disease.The late manifestation is the destruction of the intestinal wall structure and the narrowing of the intestinal cavity with scar contraction.Until now,its pathogenesis remains unclear.Although the current clinical measures for the treatment of inflammatory bowel disease can relieve inflammation,it cannot reverse the development of intestinal fibrosis and the complications such as intestinal stenosis and intestinal obstruction.Extracellular matrix plays an important role in the process of intestinal fibrosis , and its excessive deposition of extracellular matrix in the intestinal wall promotes fibrogenesis.The activation or agonist of peroxisome prolifer-ator activated receptor γ(PPARγ) may play a regulatory role in the development and progression of organ fibrosis , which can slow the progression of fibrosis.Currently,it has shown antifibrotic effects in pulmonary fibrosis , liver fibrosis and other fibrotic diseases.In the future, PPARγagonist will become a new target for the treatment of intestinal fibrosis.